1. Inicio
  2. Publicaciones
  3. Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Yagüe Caballero C
  • García López S
  • Royo Esteban A
  • Figueras Panillo L
  • de Castro L
  • Martín-Arranz MD
  • Barreiro-de Acosta M
  • Ricart E
  • de Francisco R
  • Iglesias E
  • Giordano A
  • Varela P
  • Rodríguez-Lago I
  • Rivero M
  • Sicilia B
  • Navarro-Llavat M
  • Vera I
  • Suria C
  • Barrio J
  • Calafat M
  • Calvet X
  • de la Cruz DR
  • Mesonero F
  • Martínez Pascual C
  • P Gisbert J
  • Gargallo-Puyuelo CJ
  • Monfort I Miquel D
  • Sierra M
  • Arranz L
  • Rodríguez-Gutiérrez C
  • Lorente R
  • Bermejo F
  • Márquez-Mosquera L
  • Torres Vicente G
  • Pérez-Calle JL
  • Huguet JM
  • Ramos L
  • Ponferrada-Díaz Á
  • Ceballos D
  • Diz-Lois Palomares MT
  • Sesé Abizanda E
  • Vega P
  • Pajares R
  • Santos Fernández J
  • Betoré E
  • Busquets D
  • Merino O
  • Martínez-Flores C
  • Zabana Y
  • Sampedro González MJ
  • Ortiz de Zarate J
  • Fuentes Coronel A
  • Sainz Arnau E
  • Carpio D
  • Marín-Jiménez I
  • Bujanda L
  • Camargo Camero R
  • Irabien M
  • Abanades Tercero M
  • Velayos Jiménez B
  • Robledo Andres P
  • Trapero AM
  • Delgado-Guillena PG
  • Hernández Villalba L
  • Menacho M
  • Rull Murillo N
  • Leal C
  • Alba C
  • Gómez Espín R
  • Lucendo AJ
  • Van Domselaar M
  • García Alles L
  • Iyo Miyashiro E
  • Crespo Catalá A
  • Gilabert P
  • Martín Rodríguez D
  • Navas-López VM
  • Calvo Iñiguez M
  • Ginard D
  • Martínez Pérez T
  • Domènech E
  • Casas Deza D

Grupos

Abstract

BACKGROUND: The expanding use of targeted therapies in inflammatory bowel disease has made treatment sequencing increasingly relevant, yet evidence on anti-TNF effectiveness after prior biologics with different mechanisms of action (MOA) remains limited. Our objective is to evaluate the durability of anti-TNF treatment in this scenario. METHODS: Multicentre study based on data from the ENEIDA registry. Patients who received second-line anti-TNF therapy after a first biologic with a different MOA for active luminal disease were identified. Using propensity score matching, each case was matched with three controls from two cohorts: patients treated with second-line anti-TNF after another anti-TNF and patients receiving first-line anti-TNF therapy. Treatment durability and short- and long-term clinical effectiveness were assessed. RESULTS: Sixty-six Crohn's disease patients and 117 UC patients receiving anti-TNF after other MOA were included. In CD, second-line anti-TNF therapy after a different MOA (62% ustekinumab) was associated with a higher risk of treatment discontinuation compared with first-line anti-TNF therapy (HR 1.55; 95% CI, 1.05-2.30), without significant differences in short- or long-term clinical effectiveness. In UC, anti-TNF therapy after a different MOA (90% vedolizumab) was associated with lower treatment durability compared with first-line anti-TNF therapy (HR 1.69; 95% CI, 1.31-2.19) and with anti-TNF after another anti-TNF agent (HR 1.91; 95% CI, 1.48-2.48), its remission rates significantly lower at both short- and long-term follow-up (p < 0.001). CONCLUSIONS: Anti-TNF therapy used after a different MOA is associated with reduced effectiveness and durability compared with its use as first-line therapy or after another anti-TNF agent, especially in UC.

© 2026 The Author(s). Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

Datos de la publicación

ISSN/ISSNe:
0269-2813, 1365-2036

ALIMENTARY PHARMACOLOGY & THERAPEUTICS  WILEY

Tipo:
Article
Páginas:
-
PubMed:
42581715

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Crohn's disease; anti-TNF therapy; inflammatory bowel disease; mechanism of action; treatment sequencing; ulcerative colitis

Cita

Compartir